Vivos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	1.64	3.52	24.03	18.21	0.75	1.28
Short-Term Investments	0	0	0	0.08	0	0
Cash & Cash Equivalents	1.64	3.52	24.03	18.29	0.75	1.28
Cash Growth	-53.31%	-85.36%	31.38%	2333.51%	-41.36%	-
Receivables	0.2	0.46	1.72	1.43	0.96	0.6
Other Current Assets	0.62	1.45	1.58	0.67	0.28	0.13
Total Current Assets	2.46	5.42	27.32	20.39	1.98	2.01
Property, Plant & Equipment	4.7	4.78	2.83	0.87	1.14	1.28
Long-Term Investments	0	0	0	0.81	0.79	0
Goodwill and Intangibles	3.26	3.15	3.18	2.94	3.36	4.88
Other Long-Term Assets	0.31	0.37	0.36	0.31	0.28	0.03
Total Long-Term Assets	8.27	8.3	6.37	4.93	5.57	6.19
Total Assets	10.73	13.72	33.69	25.33	7.55	8.2
Accounts Payable	2.15	1.41	0.92	0.78	1.08	0.47
Deferred Revenue	0	0	0	2.94	0	0
Current Debt	0.47	0.42	1.27	0.87	3.71	0.16
Other Current Liabilities	4.67	4.98	5.32	3.26	4.3	1.52
Total Current Liabilities	7.29	6.81	7.51	7.84	9.09	2.16
Long-Term Debt	1.52	1.99	0	0.42	0	0.53
Other Long-Term Liabilities	1.51	0.11	0.64	0.15	0.08	0.03
Total Long-Term Liabilities	3.03	2.11	0.64	0.57	0.08	0.55
Total Liabilities	10.32	8.92	8.15	8.41	9.18	2.71
Total Debt	2	2.41	1.27	1.29	3.71	0.69
Debt Growth	-17.32%	90.75%	-1.94%	-65.22%	440.32%	-
Retained Earnings	-93.05	-79.47	-55.62	-35.34	-23.28	-12.52
Shareholders' Equity	0.41	4.8	25.54	16.92	-2.94	4.83
Net Cash / Debt	-0.35	1.11	22.77	17	-2.96	0.6
Net Cash / Debt Growth	-	-95.14%	33.91%	-	-	-
Net Cash Per Share	-0.29	1.20	26.80	33.03	-6.00	1.29
Working Capital	-4.83	-1.39	19.82	12.55	-7.11	-0.15
Book Value Per Share	0.34	5.21	30.07	32.86	-5.97	10.45

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).